Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Needham analyst Ami Fadia maintains $Harmony Biosciences(HRMY.US)$ with a buy rating, and maintains the target price at $52.According to TipRanks data, the analyst has a success rate of 43.8% and a
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
Harmony Biosciences Boosted by Narcolepsy Treatment, Diversification Outlook. UBS Says
Unveiling 6 Analyst Insights On Harmony Biosciences
UBS Initiates Harmony Biosciences Holdings at Buy With $56 Price Target